Notably, when we utilized the Wnt/β-catenin agonist CHIR-99021, which is also known to be a β-catenin activator, changes in the expression of E-cadherin/N-cadherin and β-catenin were reversed, suggesting that Mist1 inhibits EMT in gastric cancer cells via the Wnt/β-catenin pathway. The gene discussed is CDH2; the disease is gastric cancer.